Back grey_arrow_rt.gif
Tenative approval for efavirenz tablets, 600 mg for PEPFAR
  On June 25, 2012, FDA granted tentative approval for a generic version of efavirenz, 600 mg, reviewed under the expedited review provisions of the President's Emergency Plan for AIDS Relief (PEPFAR). This generic formulation is manufactured by Par Formulations Private Limited, of Chennai Area, India.

"Tentative approval" means that FDA has concluded that a drug product has met all required quality, safety and efficacy standards, but is not eligible for marketing in the U.S. because of existing patent protections. Tentative approval does, however, make the product eligible for purchase outside the United States under PEPFAR. This product was reviewed under expedited review provisions for PEPFAR.

This is a generic version of Sustiva tablets, 600 mg, a product of Bristol Myers Squibb Company, which continues to be subject to patent protections.

Patent information is available in the FDA Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as theOrange Book.

As with all generic applications, FDA conducts an on-site inspection of each manufacturing facility, and of the facilities performing the bioequivalence studies, to evaluate the ability of the manufacturer to produce a quality product and to assess the quality of the bioequivalence data supporting the application prior to granting approval or tentative approval to these applications.

You can find a complete list of all Approved and Tentatively Approved Antiretrovirals in Association with the President's Emergency Plan on the FDA web site.

Richard Klein Office of Special Health Issues Food and Drug Administration

Kimberly Struble Division of Antiviral Drug Products Food and Drug Administration

  icon paper stack View Older Articles   Back to Top